Pennsylvania-based BioClinica, a provider of clinical trial management solutions, has been selected by seven new clients for the use of BioClinica’s Trident IWR (interactive web response) to help build and deploy clinical trials without the need for programming.
Trident IWR provides clinical operations personnel a way to set up, monitor, and maintain randomization and supplies for their clinical trials, in a cost-efficient and timely manner. Trident IWR does not require programming for each new clinical trial, and it configures both web and voice at the same time, potentially initiating the study start time faster.
GlaxoSmithKline signed an agreement with BioClinica to standardize on the Trident IWR system, selecting the technology as a way to manage their global trials across phase I-IV clinical trials.
Mark Weinstein, CEO of BioClinica, stated: “With seven companies making the decision to standardize their complex trials with Trident IWR in just the first quarter of 2011 alone, we are happy to confirm that our best-in-class solution is successfully providing the efficiencies, cost savings and overall support needed by today’s top pharmaceutical companies.”